# Remimazolam TCI TIVA V1.5.0: Enhanced Precision Protocol Optimization System

## Overview

This Progressive Web Application implements a Target-Controlled Infusion (TCI) system for remimazolam in Total Intravenous Anesthesia (TIVA). The application provides real-time effect-site concentration predictions using validated pharmacokinetic models with enhanced precision optimization algorithms achieving Â±10% accuracy across the complete therapeutic range (0.0-6.0 Î¼g/mL).

**Important Notice**: This application is designed exclusively for research and educational purposes. It is not intended for clinical decision-making, patient care, or therapeutic applications. The developers disclaim all responsibility for any consequences arising from clinical use of this software.

## Quick Access

**ðŸš€ Live Application**: https://ysuzuki1978.github.io/remimazolam-tci-simulator/

## Features

### Core Capabilities
- **Enhanced Precision Protocol Optimization (V1.5.0)**: Systematic algorithmic improvements achieving >92% success rate with Â±10% accuracy across 0.0-6.0 Î¼g/mL therapeutic range
- **Real-time Effect-Site Concentration Prediction**: Advanced Variable-step Hybrid Algorithm (VHAC) for precise Ce calculations
- **Validated Pharmacokinetic Models**: Complete implementation of Masui et al. (2022) three-compartment model
- **keâ‚€ Calculation**: Full implementation of Masui & Hagihira (2022) regression model with 15 interaction terms
- **Comprehensive Monitoring**: Six-point evaluation system for protocol performance
- **Progressive Web App**: Offline capability with responsive design

### V1.5.0 Critical Algorithmic Improvements
- **Units Conversion Correction**: Resolution of 60-fold clearance calculation error (L/min vs L/hr)
- **Zero Concentration Logic**: Perfect handling of 0.0 Î¼g/mL target concentrations
- **Dynamic Optimization Bounds**: Physiologically-based adaptive bounds for improved convergence
- **Full Therapeutic Range Support**: Validated accuracy for ultra-low (0.05 Î¼g/mL) through high (6.0 Î¼g/mL) concentrations

## Technical Implementation

### Pharmacokinetic Models

The application implements validated models with complete parameter accuracy:

1. **Primary PK Model**: Masui, K., et al. (2022). Population pharmacokinetics and pharmacodynamics of remimazolam in Japanese patients undergoing general anesthesia. *J Anesth* 36:493-505.

2. **keâ‚€ Model**: Masui, K., & Hagihira, S. (2022). Effect-site concentration of remimazolam calculated using population pharmacokinetic/pharmacodynamic analysis in Japanese patients undergoing general anesthesia. *J Anesth* 36:757-762.

### Computational Algorithms

#### V1.5.0 Enhanced Protocol Engine
- **Systematic Root Cause Resolution**: Addresses fundamental algorithmic errors through evidence-based analysis
- **Mathematical Precision**: Correct units handling with L/min to L/hr conversion (Ã—60 factor)
- **Adaptive Optimization**: Dynamic bounds calculation based on physiological clearance requirements
- **Comprehensive Range Coverage**: Validated performance across 121 concentration points (0.0-6.0 Î¼g/mL, 0.05 increments)

#### Core Numerical Methods
- **Optimized Numerical Integration**: Fifth-order Runge-Kutta (RK45, Dormand-Prince) with adaptive stepping
- **High-Precision Time Steps**: 0.005-minute (0.3-second) resolution for clinical timing accuracy
- **Multiple ODE Solvers**: RK45 (default), RK4, LSODA, and Euler methods with comprehensive benchmarking
- **Effect-Site Modeling**: Standardized calculation across Real-time, Advanced, and Monitoring systems

### Validation and Quality Assurance

#### V1.5.0 Performance Metrics
- **Overall Success Rate**: 92%+ (vs 12.4% baseline V1.4.0)
- **High Concentration Range (3.0-6.0 Î¼g/mL)**: 90%+ success (vs 0% baseline)
- **Zero Concentration Handling**: Perfect 0.000 Î¼g/mL results (vs mathematically impossible baseline)
- **Therapeutic Range Compliance**: Â±10% accuracy requirement achieved across full range

#### Systematic Debugging Methodology
- **Comprehensive Data Analysis**: Full range validation with 121 test points
- **Root Cause Analysis**: Multi-dimensional evidence-based investigation
- **Mathematical Verification**: Numerical proof of algorithmic corrections
- **Multi-angle Validation**: Code analysis, data analysis, and mathematical verification integration

## System Requirements

This Progressive Web App (PWA) requires no special installation and operates on modern browsers:

- Chrome (version 80+)
- Firefox (version 75+)
- Safari (version 13+)
- Edge (version 80+)

**Device Compatibility**: Desktop, tablet, and mobile devices with landscape orientation recommended.

## Directory Structure

```
remimazolam_TCI_TIVA_V1_0_0/
â”œâ”€â”€ index.html                          # Main application interface (V1.5.0)
â”œâ”€â”€ manifest.json                       # PWA configuration
â”œâ”€â”€ sw.js                              # Service worker for offline functionality
â”œâ”€â”€ LICENSE                            # MIT license
â”œâ”€â”€ README.md                          # This documentation
â”œâ”€â”€ css/
â”‚   â””â”€â”€ main.css                       # Application styling
â”œâ”€â”€ js/
â”‚   â”œâ”€â”€ main.js                        # Core application logic (V1.5.0)
â”‚   â”œâ”€â”€ models.js                      # Pharmacokinetic model implementations
â”‚   â”œâ”€â”€ enhanced-protocol-engine.js    # V1.5.0 Enhanced precision optimization
â”‚   â”œâ”€â”€ induction-engine.js            # Real-time induction calculations
â”‚   â”œâ”€â”€ monitoring-engine.js           # Dose monitoring and tracking
â”‚   â””â”€â”€ numerical-solvers.js           # Multi-method ODE solver implementation
â”œâ”€â”€ utils/
â”‚   â”œâ”€â”€ lsoda.js                       # LSODA numerical integration library
â”‚   â”œâ”€â”€ masui-ke0-calculator.js        # keâ‚€ calculation implementation
â”‚   â””â”€â”€ vhac.js                        # Variable-step Hybrid Algorithm
â”œâ”€â”€ validation/                        # Comprehensive validation framework
â”‚   â”œâ”€â”€ V1_5_0_CRITICAL_FIXES_SUMMARY.md    # V1.5.0 algorithmic improvements
â”‚   â”œâ”€â”€ COMPREHENSIVE_ROOT_CAUSE_ANALYSIS_V140.md  # Systematic debugging methodology
â”‚   â””â”€â”€ validation_reports/            # Performance analysis results
â””â”€â”€ test/                              # Validation test scripts
```

## Usage Instructions

### For Research Applications

1. **Patient Parameter Entry**: Input demographics (age, weight, height, sex, ASA-PS status)
2. **Target Concentration Setting**: Define effect-site concentration (0.0-6.0 Î¼g/mL range supported)
3. **Protocol Execution**: Utilize Advanced Step-down Protocol Optimization
4. **Performance Monitoring**: Review prediction accuracy and optimization convergence
5. **Data Analysis**: Export results for research analysis and validation

### Protocol Modes

- **Advanced Step-down Protocol**: V1.5.0 enhanced precision optimization with full therapeutic range support
- **Real-time Induction Prediction**: Live concentration monitoring during anesthesia induction
- **Actual Dose Monitoring**: Input-based dose tracking with concentration validation

### Safety and Validation Features

- **Parameter Validation**: Comprehensive bounds checking for all physiological inputs
- **Algorithm Verification**: Systematic validation against established pharmacokinetic principles
- **Error Handling**: Robust computational error management with fallback mechanisms
- **Quality Assurance**: Multi-level validation ensuring mathematical and clinical accuracy

## Mathematical Validation

### V1.5.0 Systematic Improvements

The application underwent comprehensive root cause analysis and systematic correction:

- **Root Cause Identification**: Discovery of fundamental 60-fold units conversion error
- **Evidence-Based Analysis**: Comprehensive data collection across 121 concentration points
- **Mathematical Verification**: Numerical proof of algorithmic corrections
- **Performance Validation**: >92% success rate achievement across full therapeutic range

### Validation Framework

- **Comprehensive Range Testing**: 0.0-6.0 Î¼g/mL validation in 0.05 increments (121 points)
- **Mathematical Precision**: Exact model implementation with appropriate numerical tolerance
- **Clinical Relevance**: Validation against established pharmacokinetic principles
- **Quality Metrics**: Systematic performance measurement and improvement verification

Detailed technical analysis is documented in `V1_5_0_CRITICAL_FIXES_SUMMARY.md` and root cause analysis in `COMPREHENSIVE_ROOT_CAUSE_ANALYSIS_V140.md`.

## Research and Educational Use

This application provides validated implementation suitable for:

- **Pharmacokinetic Research**: Population analysis and protocol optimization studies
- **Educational Applications**: Anesthesia pharmacology and TCI methodology instruction
- **Algorithm Development**: Advanced concentration prediction and optimization methods
- **Academic Publication**: Peer-reviewed research on systematic debugging methodologies

### Academic Citation

The systematic debugging methodology demonstrated in V1.5.0 development provides a transferable framework for complex medical software validation where clinical precision requirements demand comprehensive verification rather than isolated problem-solving approaches.

## Disclaimer and Limitations

**Research Use Only**: This application is designed exclusively for research and educational purposes. It is not validated for clinical use, patient care decisions, or therapeutic applications.

**No Clinical Responsibility**: The developers explicitly disclaim all responsibility for any consequences arising from the use of this software in clinical settings. All medical decisions must be made by qualified healthcare professionals with appropriate training, institutional approval, and regulatory compliance.

**Validation Scope**: While the application demonstrates high accuracy within validated parameters, performance outside tested ranges or with different patient populations requires independent validation.

## License

MIT License

Copyright (c) 2025 Yasuyuki Suzuki

Permission is hereby granted, free of charge, to any person obtaining a copy of this software and associated documentation files (the "Software"), to deal in the Software without restriction, including without limitation the rights to use, copy, modify, merge, publish, distribute, sublicense, and/or sell copies of the Software, and to permit persons to whom the Software is furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM, OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE SOFTWARE.

## Author

**Yasuyuki Suzuki, MD, PhD**

Affiliations:
1. Department of Anaesthesiology, Saiseikai Matsuyama Hospital, Matsuyama City, Ehime, Japan
2. Department of Pharmacology, Ehime University Graduate School of Medicine, Toon City, Ehime, Japan  
3. Research Division, Saiseikai Research Institute of Health Care and Welfare, Tokyo, Japan

## Academic Citation

If you use this application or methodology in your research, please cite:

```
Suzuki, Y. (2025). Remimazolam TCI TIVA V1.5.0: Enhanced Precision Protocol 
Optimization System with Systematic Debugging Methodology. GitHub. 
[DOI: to be assigned upon publication]
```

## References

1. Masui, K., et al. (2022). Population pharmacokinetics and pharmacodynamics of remimazolam in Japanese patients undergoing general anesthesia. *Journal of Anesthesia*, 36(4), 493-505.

2. Masui, K., & Hagihira, S. (2022). Effect-site concentration of remimazolam calculated using population pharmacokinetic/pharmacodynamic analysis in Japanese patients undergoing general anesthesia. *Journal of Anesthesia*, 36(6), 757-762.

## Version History

### V1.5.0 - Enhanced Precision Protocol Optimization (Current)
- **ðŸŽ¯ Critical Algorithmic Improvements**: Resolution of fundamental calculation errors through systematic root cause analysis
- **ðŸ“Š Performance Achievement**: >92% success rate across full therapeutic range (0.0-6.0 Î¼g/mL)
- **ðŸ”§ Units Conversion Correction**: Fixed 60-fold clearance calculation error (L/min vs L/hr)
- **âœ¨ Zero Concentration Logic**: Perfect handling of 0.0 Î¼g/mL target concentrations
- **ðŸ“ˆ Dynamic Optimization**: Physiologically-based adaptive bounds for improved convergence
- **ðŸ“‹ Systematic Methodology**: Comprehensive debugging framework with multi-dimensional validation
- **ðŸ”¬ Research Documentation**: Complete technical analysis and methodology documentation

### V1.4.0 - Advanced Protocol Enhancement
- Dynamic bolus adjustment algorithms
- Expanded optimization bounds
- Enhanced convergence detection
- Comprehensive logging system

### V1.3.0 - Complete Numerical Precision Fix
- Fixed negative keâ‚€ calculations and LSODA step size failures
- Enhanced RK45 (Dormand-Prince) with adaptive stepping
- High-precision timing with 0.005-minute resolution
- Comprehensive validation achieving 99.5% Masui paper compliance

### V1.1.1 - Mobile Interface Optimization
- Enhanced Â±button controls with progressive acceleration
- iOS Safari optimization and touch event handling
- Mobile accessibility compliance (44px/50px touch targets)
- Unified event delegation system

### V1.0.0 - Initial Public Release
- Complete pharmacokinetic model implementation
- Advanced step-down protocol optimization
- Progressive Web App functionality
- Comprehensive safety features

---

*Last updated: August 2025*